Phenotypic expression of ADAMTS13 in glomerular endothelial cells

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Tati, Ramesh ^a   Kristoffersson, Ann Charlotte ^a   Ståhl, Anne lie ^a   Mörgelin, Matthias ^a   Motto, David ^b   Satchell, Simon ^c   Mathieson, Peter ^c   Manea Hedström, Minola ^a   Karpman, Diana ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; GELATINASE B; MESSENGER RNA; RNA 18S; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; ADAMTS13 PROTEIN, MOUSE; METALLOPROTEINASE; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME RELEASE; FLOW CYTOMETRY; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS CAPILLARY; GLOMERULUS EPITHELIUM; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REAL TIME POLYMERASE CHAIN REACTION; SCANNING ELECTRON MICROSCOPY; THROMBOCYTE ACTIVATION; ANIMAL; CAPILLARY; CELL CULTURE; CHEMISTRY; CULTURE MEDIUM; CYTOLOGY; ENZYME SPECIFICITY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; GLOMERULUS; METABOLISM; THROMBOCYTE; ULTRASTRUCTURE; VASCULARIZATION;

MUS;

ADAM PROTEINS; ANIMALS; BLOOD PLATELETS; CAPILLARIES; CELLS, CULTURED; CULTURE MEDIA; ENDOTHELIAL CELLS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; HUMANS; KIDNEY GLOMERULUS; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; MICE; PHENOTYPE; RNA, MESSENGER; SUBSTRATE SPECIFICITY; VON WILLEBRAND FACTOR;

EID: 79959610720     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021587     Document Type: Article

References (40)

1. Furlan M, Robles R, Lamie B, (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87: 4223-4234.
2. Moake JL, (1986) von Willebrand factor in thrombotic thrombocytopenic purpura. Blood 67: 1523-1526.
3. Jaffe EA, Hoyer LW, Nachman RL, (1974) Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci U S A 71: 1906-1909.
4. Sporn LA, Chavin SI, Marder VJ, Wagner DD, (1985) Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest 76: 1102-1106.
5. Tsai HM, Nagel RL, Hatcher VB, Sussman, II, (1989) Multimeric composition of endothelial cell-derived von Willebrand factor. Blood 73: 2074-2076.
6. Arya M, Anvari B, Romo GM, Cruz MA, Dong JF, et al. (2002) Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 99: 3971-3977.
7. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, et al. (2002) ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100: 4033-4039.
8. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM, (1990) Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci U S A 87: 6306-6310.
9. Raife TJ, Cao W, Atkinson BS, Bedell B, Montgomery RR, et al. (2009) Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood 114: 1666-1674.
10. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, et al. (1997) Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 89: 3097-3103.
11. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, et al. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413: 488-494.
12. Tsai HM, Lian EC, (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339: 1585-1594.
13. Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, et al. (2005) Localization of ADAMTS13 to the stellate cells of human liver. Blood 106: 922-924.
14. Shang D, Zheng XW, Niiya M, Zheng XL, (2006) Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood 108: 2207-2215.
15. Turner N, Nolasco L, Tao Z, Dong JF, Moake J, (2006) Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost 4: 1396-1404.
16. Liu L, Choi H, Bernardo A, Bergeron AL, Nolasco L, et al. (2005) Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost 3: 2536-2544.
17. Suzuki M, Murata M, Matsubara Y, Uchida T, Ishihara H, et al. (2004) Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biochem Biophys Res Commun 313: 212-216.
18. Plaimauer B, Zimmermann K, Volkel D, Antoine G, Kerschbaumer R, et al. (2002) Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 100: 3626-3632.
19. Manea M, Kristoffersson A, Schneppenheim R, Saleem MA, Mathieson PW, et al. (2007) Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol 138: 651-662.
20. Manea M, Tati R, Karlsson J, Bekassy ZD, Karpman D, (2010) Biologically active ADAMTS13 is expressed in renal tubular epithelial cells. Pediatr Nephrol 25: 85-96.
21. Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, et al. (2005) Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 115: 2752-2761.
22. Vomund AN, Majerus EM, (2009) ADAMTS13 bound to endothelial cells exhibits enhanced cleavage of von Willebrand factor. J Biol Chem 284: 30925-30932.
23. Chauhan AK, Walsh MT, Zhu G, Ginsburg D, Wagner DD, et al. (2008) The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. Blood 111: 3452-3457.
24. George JN, (2000) How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 96: 1223-1229.
25. Chauhan AK, Motto DG, Lamb CB, Bergmeier W, Dockal M, et al. (2006) Systemic antithrombotic effects of ADAMTS13. J Exp Med 203: 767-776.
26. Lenz O, Striker LJ, Jacot TA, Elliot SJ, Killen PD, et al. (1998) Glomerular endothelial cells synthesize collagens but little gelatinase A and B. J Am Soc Nephrol 9: 2040-2047.
27. Huang J, Motto DG, Bundle DR, Sadler JE, (2010) Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice. Blood 116: 3653-3659.
28. Shi SR, Key ME, Kalra KL, (1991) Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741-748.
29. Vaziri-Sani F, Holmberg L, Sjoholm AG, Kristoffersson AC, Manea M, et al. (2006) Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney Int 69: 981-988.
30. Nitsche DP, Johansson HM, Frick IM, Morgelin M, (2006) Streptococcal protein FOG, a novel matrix adhesin interacting with collagen I in vivo. J Biol Chem 281: 1670-1679.
31. Herwald H, Cramer H, Morgelin M, Russell W, Sollenberg U, et al. (2004) M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell 116: 367-379.
32. Keepers TR, Psotka MA, Gross LK, Obrig TG, (2006) A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. J Am Soc Nephrol 17: 3404-3414.
33. Satchell SC, Tasman CH, Singh A, Ni L, Geelen J, et al. (2006) Conditionally immortalized human glomerular endothelial cells expressing fenestrations in response to VEGF. Kidney Int 69: 1633-1640.
34. Turner NA, Nolasco L, Ruggeri ZM, Moake JL, (2009) Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage. Blood 114: 5102-5111.
35. Powazniak Y, Kempfer AC, Pereyra JC, Palomino JP, Lazzari MA, (2011) VWF and ADAMTS13 behavior in estradiol-treated HUVEC. Eur J Haematol 86: 140-147.
36. Lanke E, Kristoffersson AC, Philips M, Holmberg L, Lethagen S, (2008) Characterization of a novel mutation in the von Willebrand factor propeptide in a distinct subtype of recessive von Willebrand disease. Thromb Haemost 100: 211-216.
37. Manea M, Kristoffersson A, Tsai HM, Zhou W, Winqvist I, et al. (2007) ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura. Eur J Pediatr 166: 249-257.
38. Shamamian P, Schwartz JD, Pocock BJ, Monea S, Whiting D, et al. (2001) Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 189: 197-206.
39. Stahl AL, Sartz L, Nelsson A, Bekassy ZD, Karpman D, (2009) Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome. PLoS One 4: e6990.
40. Tsai HM, (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87: 4235-4244.